AU2002320352A1 - Methods for treating or preventing sclerotic disorders using cd2-binding agents - Google Patents

Methods for treating or preventing sclerotic disorders using cd2-binding agents

Info

Publication number
AU2002320352A1
AU2002320352A1 AU2002320352A AU2002320352A AU2002320352A1 AU 2002320352 A1 AU2002320352 A1 AU 2002320352A1 AU 2002320352 A AU2002320352 A AU 2002320352A AU 2002320352 A AU2002320352 A AU 2002320352A AU 2002320352 A1 AU2002320352 A1 AU 2002320352A1
Authority
AU
Australia
Prior art keywords
treating
preventing
methods
binding agents
sclerotic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002320352A
Inventor
Akshay K. Vaishnaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of AU2002320352A1 publication Critical patent/AU2002320352A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002320352A 2001-07-24 2002-07-10 Methods for treating or preventing sclerotic disorders using cd2-binding agents Abandoned AU2002320352A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30768801P 2001-07-24 2001-07-24
US60/307,688 2001-07-24
US38245902P 2002-05-22 2002-05-22
US60/382,459 2002-05-22
PCT/US2002/021631 WO2003009740A2 (en) 2001-07-24 2002-07-10 Methods for treating or preventing sclerotic disorders using cd2-binding agents

Publications (1)

Publication Number Publication Date
AU2002320352A1 true AU2002320352A1 (en) 2003-02-17

Family

ID=26975880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002320352A Abandoned AU2002320352A1 (en) 2001-07-24 2002-07-10 Methods for treating or preventing sclerotic disorders using cd2-binding agents

Country Status (5)

Country Link
US (1) US7858095B2 (en)
EP (1) EP1419236A4 (en)
AU (1) AU2002320352A1 (en)
CA (1) CA2454618C (en)
WO (1) WO2003009740A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
EP1419236A4 (en) 2001-07-24 2005-08-03 Biogen Idec Inc Methods for treating or preventing sclerotic disorders using cd2-binding agents
PL1682537T3 (en) 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulators of cellular adhesion
EP1750747A1 (en) 2004-05-07 2007-02-14 Astellas US LLC Soluble lfa-3 polypeptide for treating viral disorders
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
CN101909444B (en) * 2007-11-05 2013-09-18 米迪缪尼有限公司 Methods of treating scleroderma
EP2265125B1 (en) * 2008-04-15 2019-08-14 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2011031676A2 (en) * 2009-09-10 2011-03-17 Mayo Foundation For Medical Education And Research Depleting immunosuppressive monocytes within a mammal
CA2978597A1 (en) * 2015-03-06 2016-09-15 Georgia State University Research Foundation, Inc. Integrin-targeting protein and methods of use thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
US4738927A (en) * 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
JPH0763830B2 (en) * 1985-11-26 1995-07-12 アスモ株式会社 Method of applying release agent to die casting mold
US5110906A (en) 1986-08-21 1992-05-05 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
DE260880T1 (en) 1986-09-11 1988-11-03 Dana-Farber Cancer Institute, Inc., Boston, Mass., Us METHOD FOR TRIGGERING THE CYTOTOXICITY.
WO1988005664A1 (en) 1987-01-30 1988-08-11 Jacob Gabriel Michael Partial cationization of protein-containing antigens and method of immunization and desensitization
EP0303692A4 (en) 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
DE3886237T2 (en) 1987-02-26 1994-05-05 Dana Farber Cancer Inst Inc Purification of LFA-3.
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
JP2544734B2 (en) 1987-03-24 1996-10-16 コスモ開発株式会社 Immunosuppressant
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
JP2501113B2 (en) 1987-08-27 1996-05-29 東京瓦斯株式会社 Optical displacement detection mechanism for displacement member in combustible gas equipment
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE3801511C2 (en) 1988-01-20 1996-11-14 Espe Stiftung Use of photoinitiators for the production of dental materials that can be hardened in two steps
PT89484B (en) 1988-01-22 1994-03-31 Gen Hospital Corp GENE CLONED CODES OF FUSAO PROTEINS IG-CD4 AND ITS UTILIZATION
GB2216126B (en) 1988-02-12 1992-06-03 Medical Res Council Antibodies to the antigen campath-1
EP0345466A3 (en) 1988-05-10 1991-04-17 EASTMAN KODAK COMPANY (a New Jersey corporation) Generation of chimeric antibodies in vivo by site-specific recombination
US5185441A (en) 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
JPH04504654A (en) 1988-12-23 1992-08-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ Composition and method for receptor transcription suppression activity
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5223394A (en) 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
KR0162259B1 (en) 1989-12-05 1998-12-01 아미 펙터 Chimeric antibody for detection and therapy of infectious and inflammatory lesions
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
EP0463157A4 (en) 1990-01-24 1992-06-03 Biogen, Inc. Lfa-3 as a vaccine adjuvant
JPH04506460A (en) 1990-01-26 1992-11-12 バイオジェン，インコーポレイテッド C4 binding protein fusion protein
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
IL99864A (en) 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
MX9203138A (en) * 1991-03-12 1992-09-01 Biogen Inc DOMAIN OF LINK CD2-ANTIGEN 3 (LFA-3) ASSOCIATED WITH FUNCTION LYMPHOSITES.
AU1771192A (en) 1991-03-12 1992-10-21 Biogen, Inc. Monoclonal antibodies recognizing lymphocyte function associated antigen-3
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
CA2120500A1 (en) 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AU677772B2 (en) 1991-10-07 1997-05-08 Biogen Idec Ma Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA -3 interaction
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ES2169783T3 (en) 1991-10-07 2002-07-16 Biogen Inc METHODS TO IMPROVE THE TOLERANCE OF ALOINJERTOS OR XENOINJERTOS BY ADMINISTRATION OF FIXING PROTEINS LFA-3 OR CD2.
JP2503269Y2 (en) 1992-04-02 1996-06-26 ミサワホーム株式会社 Handrail end member using curtain plate
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
AU709711B2 (en) 1994-03-08 1999-09-02 Dana-Farber Cancer Institute Methods for modulating T cell unresponsiveness
EP0804459A4 (en) * 1995-01-16 1999-05-26 Commw Scient Ind Res Org Therapeutic compound - fatty acid conjugates
SI1109570T1 (en) 1998-08-31 2006-04-30 Biogen Idec Inc Modulation of memory effector t-cells with a cd2 binding agent
ES2252999T3 (en) * 1998-08-31 2006-05-16 Biogen Idec Ma Inc. MODULATION OF EFFECT AND MEMORY T-CELLS WITH A CD2 LINK.
US6337337B1 (en) * 1998-09-03 2002-01-08 Carol J. Buck Methods for treating disorders responsive to DHFR-inhibition
HUP0303826A2 (en) * 2001-02-01 2004-03-01 Biogen, Inc. Methods for treating or preventing skin disorders using cd2-binding agents
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
EP1419236A4 (en) 2001-07-24 2005-08-03 Biogen Idec Inc Methods for treating or preventing sclerotic disorders using cd2-binding agents

Also Published As

Publication number Publication date
EP1419236A2 (en) 2004-05-19
EP1419236A4 (en) 2005-08-03
WO2003009740A2 (en) 2003-02-06
US20040265305A1 (en) 2004-12-30
WO2003009740A3 (en) 2003-12-11
CA2454618A1 (en) 2003-02-06
US7858095B2 (en) 2010-12-28
CA2454618C (en) 2012-04-03

Similar Documents

Publication Publication Date Title
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
AU2001269799A1 (en) Methods for treating various eye disorders
AU2003297761A1 (en) Methods for treating neurological language disorders
EP1414464A4 (en) Method for treating glaucoma v
AU2001285159A1 (en) Methods for treating endocrine disorders
AU2001238369A1 (en) Method for treating thyroid disorders
EP1419218A4 (en) Continuous naphtha treatment method
AU2003210597A1 (en) Methods for treating eye disorders
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
AU2002336405A1 (en) Methods for treating deodorizer distillate
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
IL157592A0 (en) Carbamate compounds for use in preventing or treating movement disorders
AU2001237939A1 (en) Methods for treating glaucoma
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
AU2002320352A1 (en) Methods for treating or preventing sclerotic disorders using cd2-binding agents
IL157588A0 (en) Carbamate compounds for use in preventing or treating psychotic disorders
AU2002326991A1 (en) Methods for treating multiple sclerosis
MXPA03001472A (en) Compounds for the treatment of addictive disorders.
AU2003237460A1 (en) Combination treatments for purinoceptor-related disorders
EP1425020A4 (en) Methods and compositions for treating apoptosis associated disorders
AU2002229795A1 (en) Method for treating sexual disorders
AU2001236909A1 (en) Method of treating disorders of the eye
AU2003228813A1 (en) Methods for treating neuronal disorders
AU2002333670A1 (en) Method for treating skin disorders
AU2002229796A1 (en) Method for treating sleep disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase